Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Douillard, Jean‐Yves; Siena, Salvatore; T. Cassidy, James; Tabernero, Josep; L. Burkes, Ronald; Barugel, Mario; Humblet, Yves; Bodoky, G.; Cunningham, David; Jassem, Jacek; Rivera, Fernando; Kocáková, Ilona; Ruff, Paul; Błasińska-Morawiec, Maria; Šmakal, Martin; Canon, Jean‐Luc; Rother, M.; S. Oliner, Kelly; Wolf, Michael; Gansert, Jennifer

doi:10.1200/jco.2009.27.4860

Public

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Published in Journal of Clinical Oncology • Oct 4, 2010

Authors:

Jean‐Yves Douillard

Salvatore Siena

James T. Cassidy

Abstract

PURPOSE: Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as monotherapy for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The Panitumumab Randomized Trial in Combinatio...

Subject

Panitumumab

Oxaliplatin

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!